8-K
filed January 17, 2025, 6:59 PM ET
CIK 0001061027
regulatory
confidence high
sentiment negative
materiality 0.60
Viracta receives Nasdaq notice for audit committee non-compliance; cure period through Dec 2025
Viracta Therapeutics, Inc.
- Nasdaq notice dated Jan 13, 2025 for failing audit committee requirement under Rule 5605(c)(2).
- Non-compliance triggered by resignation of board member Barry J. Simon, M.D. on Dec 18, 2024.
- Cure period runs until the earlier of next annual meeting or Dec 18, 2025.
- If annual meeting before June 16, 2025, compliance evidence due by June 16, 2025.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0000950170-25-006711
- form_type
- 8-K
- ticker
- null
- cik
- 0001061027
- company_name
- Viracta Therapeutics, Inc.
- filed_at
- 2025-01-17T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:02.838992+00:00
- generated_at
- 2026-05-27T22:55:29.926834+00:00
- sec_items
- ["3.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.6
- calibrated_materiality_score
- 0.6
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0000950170-25-006711
- json_url
- https://secwatch.observer/filing/0000950170-25-006711.json
- markdown_url
- https://secwatch.observer/filing/0000950170-25-006711.md
- text_url
- https://secwatch.observer/filing/0000950170-25-006711.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1061027/000095017025006711/0000950170-25-006711-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1061027/000095017025006711/virx-20250113.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ILLR
Triller gets Nasdaq bid-price exception until June 30, 2026
Triller Group Inc.
June 2, 2026, 8:26 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
May 29, 2026, the Nasdaq Hearings Panel (the
“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant
Triller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,
2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following
a successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which
modified a previous December 26, 2025 decision by a Nasdaq Hearings Panel
Filing page
SEC filing
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY
Filing page
SEC filing
NUTR
NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026
NUSATRIP Inc
June 1, 2026, 7:10 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)
from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s
non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely
file its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended
March 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req
Filing page
SEC filing
XXI
Twenty One Capital receives NYSE non-compliance notice; audit committee lacks independence; cure due June 5
Twenty One Capital, Inc.
June 1, 2026, 7:05 AM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
cator
and website references will be removed when the Company regains compliance with all NYSE quantitative and corporate governance listing
standards. The Company expects to appoint, as soon as practicable, an additional member to the audit committee who meets the independence
requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the Listed Company Manual. Forward-Looking Statements Certain statements in this periodic report are “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words indi
Filing page
SEC filing
COLA
Columbus Acquisition regains compliance with Nasdaq $50M MVLS rule; delisting risk removed
Columbus Acquisition Corp/Cayman Islands
May 29, 2026, 9:56 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
May 28, 2026, the Company the Company received a written notice from Nasdaq notifying the Company that the Staff has determined that
for the last 10 consecutive business days, from May 13, 2026 to May 27, 2026, the Company’s MVLS has been $50 million or greater.
Accordingly, the Company has regained compliance with the MVLS Rule and the Staff has indicated that the matter is now closed. 1 SIGNATURES Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. Columbus
Acq
Filing page
SEC filing
CSAI
Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing
CLOUDASTRUCTURE, INC.
May 29, 2026, 5:09 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
May 26, 2026, Cloudastructure,
Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq
Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for
the period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which
requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional
time to review and confirm the accounting treatment for its outstand
Filing page
SEC filing
CETY
Clean Energy Technologies receives Nasdaq delisting notice for late Q1 filing
Clean Energy Technologies, Inc.
May 29, 2026, 4:57 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
May 26, 2026, Clean Energy Technologies, Inc. (the “ Company ”) received a written notice (the “ Notice ”)
from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not
in compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”) because the Company had not yet filed its Quarterly
Report on Form 10-Q for the period ended March 31, 2026 (the “ Quarterly Report ”). The
Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The Notice has
no immediate effect on the listing
Filing page
SEC filing
GURE
Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing
GULF RESOURCES, INC.
May 29, 2026, 4:45 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Comparable filing
May 26, 2026, Gulf Resources
(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq
Stock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for
the quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form
10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq
Listing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.